TYRA Tyra Biosciences, Inc.

Overview and Growth

In fiscal 2025, Tyra Biosciences, Inc. reported net loss of $119.95M. The company reported diluted EPS of -$2.01, adding a shareholder-level measure to the absolute income figures considered below. The diluted weighted-average share count was 59.60M, linking total earnings with the per-share result received by shareholders. Diluted shares moved 4.2% from 57.22M in fiscal 2024, leaving the current share base higher year over year. The company employed $282.61M of total assets, the balance-sheet base supporting its current operating and cash-flow results.

Profitability

The company recorded an operating loss of $132.76M after the reported operating expense base. The company ended the period with a net loss of $119.95M, extending the operating result through all remaining items. EBITDA was negative $132.22M, showing a deficit before interest, taxes, depreciation, and amortization. Income tax expense totaled $0.00, providing the reported tax component that separates pretax and after-tax earnings. The loss-to-equity relationship was 46.3%, placing the bottom-line deficit against shareholder capital. Relative to total assets, the net loss represented 42.4%. The bottom-line deficit increased from $86.48M in fiscal 2024 to $119.95M.

Liquidity and Capital Structure

Total assets were $282.61M, supported by $23.43M of liabilities and $259.18M of shareholder equity. The near-term balance sheet paired $265.45M of current assets with $18.09M of current liabilities at the reporting date. The current ratio was 14.67x, with current assets exceeding current liabilities and providing a short-term liquidity cushion. Reported cash and equivalents were $77.39M, separating immediately recognizable cash resources from the rest of the current-asset base. Measured only with cash and equivalents, coverage of current liabilities was 427.7%, excluding receivables and other current assets. Book equity represented 91.7% of total assets, quantifying the balance-sheet share supported by shareholder capital. The liabilities-to-assets relationship was 8.3%, placing reported obligations against the full positive asset balance. Measured against total assets, cash and equivalents represented 27.4%, a balance-sheet composition measure rather than a liquidity forecast. The asset base changed 22.3% from $363.56M in fiscal 2024, leaving current total assets lower year over year. Against $343.15M of equity in fiscal 2024, the current book-equity balance moved 24.5% and ended lower. The reported cash balance changed 15.9% from $91.97M in fiscal 2024, ending lower year over year.

Cash Flow and Earnings Quality

Operating activities used $95.14M of cash, resulting in an operating cash outflow for the year. Capital spending of $141.00K added to the period’s operating cash use, reinforcing the overall cash deficit after investment for the year. Negative free cash flow was $95.28M, leaving a cash deficit after capital spending and reducing financial flexibility. The free-cash-flow deficit equaled 33.7% of total assets, placing the cash shortfall against the company’s resource base. The operating cash outflow widened to $95.14M from $69.77M in fiscal 2024.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Oct 21, 2026.